---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-218026"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:54:30.843384+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# UroGen Q2 Jelmyto revenue $16.6M (+28% YoY); reaffirms FY22 guidance $70-80M

## Summary
- Q2 Jelmyto net revenue $16.6M, up 22% QoQ and 28% YoY from $13.0M.
- Net loss $26.7M ($1.18/share) vs $26.2M ($1.17/share) in Q2 2021.
- Cash and marketable securities $112.4M as of June 30, 2022.
- Reaffirms FY2022 Jelmyto revenue guidance of $70-80M; reduces operating expense forecast to $130-140M.
- Enrollment in Phase 3 ENVISION trial for UGN-102 on track for completion by end of 2022.

## SEC filing metadata
- accession: 0001193125-22-218026
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312522218026/0001193125-22-218026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312522218026/d338870d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-218026
- JSON: https://secwatch.observer/filing/0001193125-22-218026.json
- Plain text: https://secwatch.observer/filing/0001193125-22-218026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.